Wu Jiajun, Pu Liqu, Zhou Hui, Qu Wenjia, Zhao Dandan, Liu Chunmeng, Dong Xuewen, Zhang Fuwen
School of Eye.
School of Nursing.
Medicine (Baltimore). 2020 Dec 4;99(49):e23093. doi: 10.1097/MD.0000000000023093.
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). There is no specific cure for this disease, and the clinical management mainly depends on supportive treatment. This disease may affect SARS-CoV-2 conjunctivitis. Yuxingcao eye drops is used in treating COVID-19 conjunctivitis in China.
A comprehensive literature search will be conducted. Two methodological trained researchers will read the title, abstract, and full texts and independently select the qualified literature according to inclusion and exclusion criteria. After assessment of the risk of bias and data extraction, we will conduct meta-analyses for outcomes related to COVID-19 conjunctivitis. The heterogeneity of data will be investigated by Cochrane X and I tests. Then publication bias assessment will be conducted by funnel plot analysis and Egger test.
The results of our research will be published in a peer-reviewed journal.
Our study aims to systematically present the clinical evidence of Yuxingcao eye drops in treating COVID-19 conjunctivitis, which will be of significant meaning for further research and clinical practice.
PROSPERO CRD42020209059.
2019冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的全球大流行疾病。该疾病尚无特效治愈方法，临床管理主要依赖支持性治疗。这种疾病可能会引发SARS-CoV-2结膜炎。在中国，鱼腥草滴眼液被用于治疗COVID-19结膜炎。
将进行全面的文献检索。两名经过方法学培训的研究人员将阅读标题、摘要和全文，并根据纳入和排除标准独立选择合格文献。在评估偏倚风险和进行数据提取后，我们将对与COVID-19结膜炎相关的结局进行荟萃分析。将通过Cochrane X和I检验调查数据的异质性。然后通过漏斗图分析和Egger检验进行发表偏倚评估。
我们的研究结果将发表在同行评审期刊上。
我们的研究旨在系统呈现鱼腥草滴眼液治疗COVID-19结膜炎的临床证据，这对进一步的研究和临床实践具有重要意义。
PROSPERO注册号：PROSPERO CRD42020209059。
